(Press-News.org) A clinical trial supported by the National Institutes of Health (NIH) is testing an experimental treatment designed to help people suffering the effects of dengue, a mosquito-borne viral disease. The study is supported by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), and will involve exposing adult volunteers to a weakened strain of dengue virus that causes a mild form of the disease and administering an investigational therapeutic at various doses to assess its safety and ability to lessen symptoms.
Dengue is transmitted via infected Aedes mosquitoes and sickens as many as 400 million people each year, primarily in tropical and subtropical parts of the world, according to the U.S. Centers for Disease Control and Prevention. In 2024, dengue cases surged to record levels in the Americas with local U.S. transmission reported in Arizona, California, Florida, Hawaii, and Texas. Dengue is endemic in Puerto Rico, which reported nearly 1,500 cases last year. Most people with dengue do not develop symptoms, but those who do commonly experience severe headache and body aches, nausea and vomiting, fever and rash. One in 20 people who get sick with dengue progress to severe illness, which may lead to shock, internal bleeding, and death. There is currently no Food and Drug Administration-approved treatment for dengue.
“When caring for a patient who is critically ill with dengue, healthcare providers have few options other than providing supportive care,” said NIAID Director Jeanne Marrazzo, M.D., M.P.H. “We must find safe and effective therapeutics to provide much-needed relief to people suffering from dengue.”
The new clinical trial will test the ability of AV-1, an investigational human monoclonal antibody therapeutic developed by AbViro (Bethesda, Maryland), to mitigate clinical symptoms when administered before and after dengue virus infection. The results of a previously completed NIAID-supported Phase 1 trial indicated that AV-1 is safe in humans, providing the basis for the new clinical trial to test its safety and efficacy.
The Phase 2 clinical trial will enroll at least 84 healthy adult volunteers at two sites: the Johns Hopkins Bloomberg School of Public Health Center for Immunization Research in Baltimore, and the University of Vermont Vaccine Testing Center in Burlington. Following an initial screening and physical examination, volunteers will be randomly assigned to one of two groups. One group will receive AV-1 one day prior to being challenged with a mild strain of dengue virus, and the other will receive AV-1 four days after being challenged with the dengue virus. Each group will be further subdivided to receive 100 mg, 300 mg, or 900 mg of AV-1, delivered in a 60-minute intravenous infusion. For each of the three dosage levels, 12 participants will receive the investigational monoclonal antibody, and two will receive a placebo.
Before or after AV-1 dosing, each volunteer will receive an injection of attenuated (weakened) dengue virus. In earlier studies using this challenge virus, most volunteers developed a rash, and some had other mild dengue symptoms, such as joint and muscle pain or headache. None of the volunteers developed dengue fever or severe dengue.
Volunteers will participate in regular follow-up visits with study staff for at least 155 days to carefully monitor the effects of the investigational monoclonal antibody. Through physical exams, diary cards and blood samples, researchers will document how the volunteers’ immune systems respond to the dengue virus challenge, how quickly the virus vanishes from their bloodstream and any symptoms they may experience. The researchers will use this information to determine how AV-1 affects the volunteers’ ability to recover from dengue compared to placebo and to determine the dosages at which AV-1 may be effective.
If AV-1 shows promising results in this clinical trial, researchers may pursue further clinical evaluations of its safety and efficacy against dengue virus. For more information about the study, visit ClinicalTrials.gov and search the identifier NCT06799741.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.
NIH...Turning Discovery Into Health®
END
Sound plays a significant and often poignant part of skateboarders’ relationship with their sport, a new study shows.
Skateboarders develop the skill to tune into the noise of urban surfaces. They both hear and feel noise and this means images and videos alone are a poor insight into the sport. They use sound to verify the success of their manoeuvres, judge the veracity and capacity of surfaces for use and as a social cue. For some the sensory overload of skateboarding is therapeutic and it helps them connect with others skating nearby.
But ...
ST. LOUIS – Research from Saint Louis University (SLU) and the University of Nevada, Reno School of Medicine finds that some of the most-watched ads promote the worst food options for adults with chronic health conditions.
The findings published online on Jan. 30 in JAMA Network analyzed advertisements transmitted during televised NFL games in the U.S. to assess the nutritional content by serving.
The study found that store-bought foods and quick-service restaurants advertised during NFL games, the most watched sporting events in the U.S., ...
DALLAS, Jan. 31, 2025 — Academy Award-nominated actress and host Sharon Stone, alongside musical guests Sara Bareilles and Suki Waterhouse, headlined a roster of powerful players in music, entertainment, fashion and philanthropy to officially mark the start of American Heart Month at the Red Dress Collection® Concert on Thursday, January 30. The fashion-forward, musical celebration in New York City serves as the national marquee event for the American Heart Association’s Go Red for Women® movement, celebrating progress made while calling for a renewed commitment to the fight against cardiovascular disease, the number one killer ...
UNDER EMBARGO UNTIL: Jan. 31, 2025, 10:15 a.m. MST
Media Contact: Karen Addis, APR, karen@addispr.com, +1 (301) 787-2394
One of the Largest Studies on Preterm Birth Finds a Maternal Biomarker Test Significantly Reduces Neonatal Morbidities and Improves Neonatal Outcomes
Denver, Colo. ― Preterm birth ― defined as delivery before the 37th week of pregnancy — is one of the leading causes of infant deaths in the United States. Babies born prematurely are also at an increased risk of ...
Denver, Colo. ― Anemia during pregnancy is a common occurrence and often due to iron deficiency. It is a global public health problem, affecting an estimated 37 percent of pregnant individuals, according to the World Health Organization. Iron deficiency anemia is associated with increased rates of pregnancy-related problems, such as going into labor prematurely, hemorrhaging and, in some cases, even death. For the infant, maternal iron deficiency also can have long-term implications on their overall health and development.
Current obstetric guidelines recommend ...
CLEVELAND—Psoriasis, a painful and uncomfortable inflammatory skin condition that affects millions worldwide, flares up from the activity of disease- and infection-protecting immune cells.
In a new study, researchers at Case Western Reserve University School of Medicine have determined that a protein called NF-kB c-Rel can intensify the condition’s symptoms when activated by signals from the body’s immune system. Understanding how “c-Rel” affects skin inflammation could lead to new treatments, they said.
The study, published recently in eBioMedicine, examined how ...
MINNEAPOLIS/ST. PAUL (01/31/2025) — Portable MRI (pMRI) technologies are rapidly transforming the landscape of neuroscience research, allowing neuroscientists to acquire brain data in community settings outside the hospital for the first time. But as neuroscientists increase access to MRI technology and move their research from a lab environment to broad community settings, they face novel ethical, legal, and societal issues (ELSI).
To prepare neuroscientists to address these challenges, an interdisciplinary team of scientists, ethicists, and legal experts, supported by an NIH BRAIN Initiative grant, analyzed the issues. The team released the first-ever checklist ...
Leipzig. Over the next few years, climate researchers from Germany aim to achieve a breakthrough in the radiative properties of clouds by describing the corresponding processes not just one-dimensionally, as has been the case up to now, but three-dimensionally in future. Capturing clouds and radiation in 3D is seen as an important step towards undistorted remote sensing of the atmosphere and improved modelling of climate and weather. The new research group of the German Research Foundation (DFG) brings together experts in atmospheric radiation, high-resolution ...
It is well known that consuming sugary drinks increases the risk of diabetes, but the mechanism behind this relationship is unclear. Now, in a paper publishing January 31 in the Cell Press journal Cell Metabolism, researchers show that metabolites produced by gut microbes might play a role. In a long-term cohort of US Hispanic/Latino adults, the researchers identified differences in the gut microbiota and blood metabolites of individuals with a high intake of sugar-sweetened beverages. The altered metabolite profile ...
Researchers from the Tanenbaum group at the Hubrecht Institute have developed a new microscopy technique to observe how ribosomes function in cells. With this method, they can monitor individual ribosomes as they convert mRNA into proteins. The researchers discovered that ribosomes help each other when encountering difficulties, a process they refer to as ‘ribosome cooperativity’. This technique and the findings, published in Cell, provide insights into how proteins are made and offer other researchers a tool to better study mRNA translation.
Our DNA contains genetic information essential for ...
